New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: High-resolution imaging is the gold standard to measure the functional and biological features of bone lesions. Imaging markers have allowed the characterization both of tumour heterogeneity and metabolic data. Besides, ongoing studies are evaluating a combined use of "imaging markers", such as SUVs, MATV, TLG, ADC from PET and MRI techniques respectively, and several "biomarkers" spanning from chemokine immune-modulators, such as PD-1, RANK/RANKL, CXCR4/CXCL12 to transcription factors, such as TP53, RB1, MDM2, RUNX family, EZH2, YY1, MAD2. Osteoimmunology may improve diagnosis and prognosis leading to precision medicine in bone lesion treatment. Areas covered: We investigated modalities (molecular and imaging approach) useful to identify bone lesions deriving both from primary bone tumours and from osteotropic tumours, which have a higher incidence, prevalence and prognosis. Here, we summarized the recent advances in imaging techniques and osteoimmunology biomarkers which could play a pivotal role in personalized treatment. Expert Commentary: Although imaging and molecular integration could allow both early diagnosis and stratification of cancer prognosis, large scale clinical trials will be necessary to translate pilot studies in the current clinical setting.

Original languageEnglish
JournalExpert Review of Clinical Immunology
DOIs
Publication statusE-pub ahead of print - Dec 20 2018

Fingerprint

Allergy and Immunology
Bone and Bones
Molecular Imaging
Biomarkers
Neoplasms
Precision Medicine
Early Detection of Cancer
Chemokines
Transcription Factors
Clinical Trials
Incidence
Therapeutics

Cite this

@article{327b2c98477449b19e97426f1f12f679,
title = "New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions",
abstract = "INTRODUCTION: High-resolution imaging is the gold standard to measure the functional and biological features of bone lesions. Imaging markers have allowed the characterization both of tumour heterogeneity and metabolic data. Besides, ongoing studies are evaluating a combined use of {"}imaging markers{"}, such as SUVs, MATV, TLG, ADC from PET and MRI techniques respectively, and several {"}biomarkers{"} spanning from chemokine immune-modulators, such as PD-1, RANK/RANKL, CXCR4/CXCL12 to transcription factors, such as TP53, RB1, MDM2, RUNX family, EZH2, YY1, MAD2. Osteoimmunology may improve diagnosis and prognosis leading to precision medicine in bone lesion treatment. Areas covered: We investigated modalities (molecular and imaging approach) useful to identify bone lesions deriving both from primary bone tumours and from osteotropic tumours, which have a higher incidence, prevalence and prognosis. Here, we summarized the recent advances in imaging techniques and osteoimmunology biomarkers which could play a pivotal role in personalized treatment. Expert Commentary: Although imaging and molecular integration could allow both early diagnosis and stratification of cancer prognosis, large scale clinical trials will be necessary to translate pilot studies in the current clinical setting.",
author = "Concetta Schiano and Andrea Soricelli and {de Nigris}, Filomena and Claudio Napoli",
year = "2018",
month = "12",
day = "20",
doi = "10.1080/1744666X.2019.1561283",
language = "English",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions

AU - Schiano, Concetta

AU - Soricelli, Andrea

AU - de Nigris, Filomena

AU - Napoli, Claudio

PY - 2018/12/20

Y1 - 2018/12/20

N2 - INTRODUCTION: High-resolution imaging is the gold standard to measure the functional and biological features of bone lesions. Imaging markers have allowed the characterization both of tumour heterogeneity and metabolic data. Besides, ongoing studies are evaluating a combined use of "imaging markers", such as SUVs, MATV, TLG, ADC from PET and MRI techniques respectively, and several "biomarkers" spanning from chemokine immune-modulators, such as PD-1, RANK/RANKL, CXCR4/CXCL12 to transcription factors, such as TP53, RB1, MDM2, RUNX family, EZH2, YY1, MAD2. Osteoimmunology may improve diagnosis and prognosis leading to precision medicine in bone lesion treatment. Areas covered: We investigated modalities (molecular and imaging approach) useful to identify bone lesions deriving both from primary bone tumours and from osteotropic tumours, which have a higher incidence, prevalence and prognosis. Here, we summarized the recent advances in imaging techniques and osteoimmunology biomarkers which could play a pivotal role in personalized treatment. Expert Commentary: Although imaging and molecular integration could allow both early diagnosis and stratification of cancer prognosis, large scale clinical trials will be necessary to translate pilot studies in the current clinical setting.

AB - INTRODUCTION: High-resolution imaging is the gold standard to measure the functional and biological features of bone lesions. Imaging markers have allowed the characterization both of tumour heterogeneity and metabolic data. Besides, ongoing studies are evaluating a combined use of "imaging markers", such as SUVs, MATV, TLG, ADC from PET and MRI techniques respectively, and several "biomarkers" spanning from chemokine immune-modulators, such as PD-1, RANK/RANKL, CXCR4/CXCL12 to transcription factors, such as TP53, RB1, MDM2, RUNX family, EZH2, YY1, MAD2. Osteoimmunology may improve diagnosis and prognosis leading to precision medicine in bone lesion treatment. Areas covered: We investigated modalities (molecular and imaging approach) useful to identify bone lesions deriving both from primary bone tumours and from osteotropic tumours, which have a higher incidence, prevalence and prognosis. Here, we summarized the recent advances in imaging techniques and osteoimmunology biomarkers which could play a pivotal role in personalized treatment. Expert Commentary: Although imaging and molecular integration could allow both early diagnosis and stratification of cancer prognosis, large scale clinical trials will be necessary to translate pilot studies in the current clinical setting.

U2 - 10.1080/1744666X.2019.1561283

DO - 10.1080/1744666X.2019.1561283

M3 - Article

C2 - 30570412

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

ER -